Gyala Therapeutics is a preclinical stage biotechnology company focused on developing novel CAR-T cell therapies to treat hematologic cancers with unmet clinical need.
Hematologic or blood cancers are the fifth most common type of cancer in the world with 1.3 million new cases diagnosed in 2020.
Here's how we got started
From Hospital Clínic-IDIBAPS
Founded in 2020 as a spin-off from Hospital Clínic de Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Gyala builds on the expertise of these renowned institutions in the development of CAR-T cell therapies for cancer.
The ARI Project
This expertise stems from the ARI Project, a pioneering academic initiative launched in 2016 at Hospital Clínic de Barcelona, which led to the development of ARI-0001 (approved in Spain under hospital exemption for the treatment of adult acute lymphoblastic leukemia) and ARI-0002 (approved in Spain under hospital exemption for the treatment of multiple myeloma) and the successful treatment of hundreds of patients with hematological malignancies in Spain.